Richard F. Ambinder

M.D., Ph.D.

Scientific Advisory Board

Richard Ambinder earned a BA in biochemistry at Harvard College, an MD and later a PhD at the Johns Hopkins School of Medicine. He did his training in internal medicine and in oncology at the Johns Hopkins Hospital. His special areas of interest are EBV and associated malignancies, KSHV and associated malignancies, Hodgkin and non-Hodgkin lymphoma, bone marrow transplantation. His major contributions have been in mapping functional domains of the EBV EBNA1 protein, development of the EBER in situ hybridization assay for characterizing EBV in pathologic specimens, characterization of the EBV-association of AIDS brain lymphoma and Hodgkin lymphoma, establishment and characterization of one of the widely studied PEL cell lines, application of EBV tumor DNA measurements for tumor response monitoring, and application of transplant-based approaches to patients with AIDS malignancies. He is one of the leaders of the Division of Hematologic Malignancies at Johns Hopkins and of the Hematologic Malignancies and BMT Program in the Sidney Kimmel Cancer Center.